bodyType

customContents

entityId

entityUuid

articlePageQuery

filter

article

articleBaseAdvertisingInfoArticle

articleListArticle

articleSeoArticle

helpersCheckIsPostiesArticle

hooksArticleAcknowledgementGateOverlayArticle

hooksTrackPageViewArticle

hooksContentInterestArticle

articleLinkingDataContent

hooksAmpRedirectArticle

articleSchemaContent

liveArticle

advertZone

sentiment

contentLock

topics

types

sections

moreOnThisArticles

urlAlias

commentCount

authorLocations

authors

corrections

sponsorType

displaySlideShow

multimediaEmbed

printHeadline

seriesContainer

socialHeadline

headline

flag

firstTopic

glossary

flattenTypeIds

publishedDate

additionalInfoBoxes

quizIds

images

image

relatedLinks

relatedNewsletters

__typename

createdDate

sponsor

paywallTypes

pdfFiles

seriesReverseOrder

series

disableOffPlatformContent

published

updatedDate

summary

subHeadline

body

keywords

readingTime

customTimezone

liveContents

SCMP Reporter

Fund management firm Value Partners has clarified that it does not hold stock in Far East Pharmaceutical Technology and has not conducted any trade in the stock in recent weeks. A report yesterday on Page A1 incorrectly said that Value Partners sold shares in the firm on Thursday.



Hong Kong’s Phase Scientific gets US$34 million to advance test for cancer risk factor HPV

Global fund managers win China approval to launch onshore funds as country opens up market

Insider activity quiet ahead of Lunar New Year, funds take the spotlight

Value Partners profit slumps 96pc

Value Partners

Corrections & clarifications